The global chemotherapy-induced neutropenia treatment market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). One of the major factors that are fuelling the market is the increased use of chemotherapy in the treatment of neutropenia. The colony-stimulating factor therapy is heavily being used for the treatment of cancer. The added benefit of the colony-stimulating factor is the ability to help bone marrow in developing white blood cells. For instance, in June 2019, Amgen Inc. and Allergan PLC announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI for all approved indications of the reference product, Herceptin for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer. The FDA approval of KANJINTI is an important milestone for the biosimilars portfolio, providing an additional treatment option for patients across three types of cancer.
Browse the full report description of “Global Chemotherapy-Induced Neutropenia Treatment Market Size, Share & Trends Analysis Report by Therapy Type (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Transfusion, and Others), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/chemotherapy-induced-neutropenia-treatment-market
For instance, in July 2019, Amgen Inc. and Allergan PLC announced that MVASI, a biosimilar to Avastin, is now available in the United States (U.S.). MVASI, the first oncology therapeutic biosimilar approved by the U.S. Food and Drug Administration (FDA), is approved for the treatment of five types of cancer: in combination with chemotherapy for metastatic colorectal cancer (mCRC), in combination with chemotherapy for non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; in combination with interferon-alfa for metastatic renal cell carcinoma, and combination with chemotherapy for persistent, recurrent, or metastatic cervical cancer.
For instance, in February 2021, the US Food and Drug Administration approved Cosela as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin-dependent kinase 4/6, a type of enzyme.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Therapy Type
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - including, Amgen, Inc., Sanofi S.A., Novartis International AG, Lupin Pharmaceuticals, Inc., and Allergan PLC among others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Chemotherapy-Induced Neutropenia Treatment Market Report Segment
By Therapy Type
By Distribution Channel
Global Chemotherapy-Induced Neutropenia Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/chemotherapy-induced-neutropenia-treatment-market